Literature DB >> 7714488

Symptomatic mumps virus reinfections.

J P Gut1, C Lablache, S Behr, A Kirn.   

Abstract

Although natural mumps virus infection is believed to induce lifelong immunity, our laboratory was confronted with 82 patients who developed mumps-evoking lesions but exhibited serological evidence of a booster immune response, namely a rise or a high titer of virus-specific IgG, without IgM. In order to provide arguments favoring the existence of recurrent mumps attacks, the age, symptomatology, and humoral response of these patients (group 1) were compared to that of 82 randomly selected true primary infected patients (group 2), 10 parainfluenza virus-infected patients (group 3), and 20 noninfected mumps-immune subjects (group 4). Enzyme-linked immunosorbent assay (ELISA) procedures with different viral antigenic preparations were used for determination of specific IgM, IgA, IgG, IgG subclasses, and IgG avidity. The patients of group 1, older than those of group 2 (28 vs. 10 years, P < 0.0001), presented a significantly less severe and less typical symptomatology. Against the whole virus they exhibited IgG of higher avidity (P < 0.001), a lower prevalence and titer of IgA (10 vs. 68%, P < 0.0001 and 278 vs. 5,009, P < 0.001, respectively). Values obtained for IgG 1, 2, and 3 were significantly different between the two groups. Prevalence and absorbance of nucleocapsid-directed IgG 3 were significantly lower in group 1 (27 vs. 46%, P < 0.01 and 0.444 vs. 0.869, P < 0.01, respectively). A significant discrepancy also allowed patients from group 1 to be distinguished from those of groups 3 and 4.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7714488     DOI: 10.1002/jmv.1890450104

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  14 in total

1.  Estimates of mumps seroprevalence may be influenced by antibody specificity and serologic method.

Authors:  Donald R Latner; Marcia McGrew; Nobia J Williams; Sun B Sowers; William J Bellini; Carole J Hickman
Journal:  Clin Vaccine Immunol       Date:  2013-12-26

2.  Enzyme-linked immunospot assay detection of mumps-specific antibody-secreting B cells as an alternative method of laboratory diagnosis.

Authors:  Donald R Latner; Marcia McGrew; Nobia Williams; Luis Lowe; Roniel Werman; Eli Warnock; Kathleen Gallagher; Peter Doyle; Sandra Smole; Susan Lett; Noelle Cocoros; Alfred DeMaria; Raimond Konomi; Cedric J Brown; Paul A Rota; William J Bellini; Carole J Hickman
Journal:  Clin Vaccine Immunol       Date:  2010-11-03

3.  Evaluation of antibodies reactive with Campylobacter jejuni in Egyptian diarrhea patients.

Authors:  T F Ismail; M O Wasfy; B A Oyofo; M M Mansour; H M El-Berry; A M Churilla; S S Eldin; L F Peruski
Journal:  Clin Diagn Lab Immunol       Date:  1997-09

Review 4.  Mumps: an Update on Outbreaks, Vaccine Efficacy, and Genomic Diversity.

Authors:  Eugene Lam; Jennifer B Rosen; Jane R Zucker
Journal:  Clin Microbiol Rev       Date:  2020-02-26       Impact factor: 26.132

5.  Serum antibody responses in children with rotavirus diarrhea can serve as proxy for protection.

Authors:  J Xu; P Dennehy; H Keyserling; L E Westerman; Y Wang; R C Holman; J R Gentsch; R I Glass; B Jiang
Journal:  Clin Diagn Lab Immunol       Date:  2005-02

6.  Characterization of large mumps outbreak among vaccinated Palestinian refugees.

Authors:  Musa Y Hindiyeh; Yair Aboudy; Mahmoud Wohoush; Lester M Shulman; Daniela Ram; Tal Levin; Tamar Frank; Flavia Riccardo; Mohamad Khalili; Elias-Shlash Sawalha; Maysoun Obeidi; Guido Sabatinelli; Zehava Grossman; Ella Mendelson
Journal:  J Clin Microbiol       Date:  2009-01-14       Impact factor: 5.948

7.  Analysis of mumps vaccine failure by means of avidity testing for mumps virus-specific immunoglobulin G.

Authors:  M Narita; Y Matsuzono; Y Takekoshi; S Yamada; O Itakura; M Kubota; H Kikuta; T Togashi
Journal:  Clin Diagn Lab Immunol       Date:  1998-11

8.  Virus genotypes and responses of serum-specific antibodies in children with primary mumps and mumps reinfection.

Authors:  Rika Sakata; Akira Nagita; Minoru Kidokoro; Atsushi Kato; Keiki Ogino
Journal:  Pediatr Res       Date:  2015-08-12       Impact factor: 3.756

9.  Antigenic differences between vaccine and circulating wild-type mumps viruses decreases neutralization capacity of vaccine-induced antibodies.

Authors:  M Šantak; M Lang-Balija; J Ivancic-Jelecki; T Košutić-Gulija; S Ljubin-Sternak; D Forcic
Journal:  Epidemiol Infect       Date:  2012-09-07       Impact factor: 4.434

10.  Long-term persistence of mumps antibody after receipt of 2 measles-mumps-rubella (MMR) vaccinations and antibody response after a third MMR vaccination among a university population.

Authors:  Anand A Date; Moe H Kyaw; Alison M Rue; Julie Klahn; Leann Obrecht; Terry Krohn; Josh Rowland; Steve Rubin; Thomas J Safranek; William J Bellini; Gustavo H Dayan
Journal:  J Infect Dis       Date:  2008-06-15       Impact factor: 7.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.